In This Section      
 

Search Results

A total of 207 matching records were found.

A085
A Pilot Trial of AVD in addition to Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10005
10005 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10015
10015 A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10020
10020 A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10057
10057 Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10070
Phase 1/2 study of navitoclax plus vistusertib in patients with relapsed small cell lung cancer (SCLC) and other solid tumors (ETCTN10070)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10075
10075 A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia (ETCTN)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10107
10107 Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma (ETCTN)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10131
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel (ETCTN10131)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10147
10147 A Phase II randomized study of topotecan/carboplatin with or without veliparib in advanced myeloproliferative disorders and chronic myelomonocytic leukemia

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN9767
9767 An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN9947
9947 A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without M6620 (VX-970) in Metastatic Urothelial Carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN9952
9952 Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

G0264
G0264 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J0656
A Phase I efficacy and safety study of HPV16-specific therapeutic DNA-Vaccinia vaccination in combination with topical imiquimod, in patients with HPV16 high grade cervical dysplasia (CIN2/3)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J0859
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J09100
J09100- A safety and feasibility trial of boost vaccinations of a lethally irradiated, allogeneic pancreatic tumor cell vaccine transfected with the GM-CSF gene given alone or in combination with either a single intravenous dose or daily metronomic oral doses

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1055
Reduced intensity, partially HLA mismatched allogeneic BMT for hematologic malignancies using donors other than first-degree relatives

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J11114
A Multicenter Access and Distribution Protocol for unlicensed cryopreserved Cord Blood Units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J11120
A phase II trial of low dose fractionated radiation therapy as a chemo-potentiator of salvage temozolomide for recurrent anaplastic astrocytoma and glioblastoma multiforme

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J11143
Multiparametric MRI for assessing radiotherapy treatment response of prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12106
A Phase II Trial of Reduced Intensity Conditioning of Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplant for High-risk Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12121
A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J12138
J12138, A Phase II trial to improve outcomes in patients with resected pancreatic adenocarcinoma at high risk for recurrence using epigenetic therapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J1284
Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy with Immediate Tissue Expander Reconstruction

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J13101
J13101 "A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors".

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J13104
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)

Sites: Suburban Hospital, Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J13105
Early Detection of Pancreatic Cystic Neoplasms

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1331
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1-infected individuals

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1353
A Phase II Study of Epigenetic Therapy with Azacitidine and Entinostat with Concurrent Nivolumab in Subjects with Metastatic Non-Small Cell Lung Cancer.

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1365
J1365: Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1366
Role of Human Papillomavirus in Head and Neck Squamous Cell Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1367
A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1380
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

J1394
Cancer of the Pancreas Screening-5 A multi-center clinical trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1409
Immune Evaluation Study of Sipuleucel-T in African American and non-African American Men with Castrate Resistant Prostate Cancer (Karmanos Cancer Institute protocol # 2013-108)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J14106
Non-invasive Detection of Cancer DNA in Blood and Urine

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1412
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J14126
J14126, A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1414
Neoadjuvant Nivolumab, or Nivolumab in combination with Ipilimumab, in Resectable Non-Small-Cell Lung Cancer

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore

J1416
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J14166
Prospective evaluation of high-dose (8 g/m2) systemic methotrexate in patients with breast cancer and leptomeningeal metastasis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J14179
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m² IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m² SC/IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m² SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1424
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients with Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1426
“A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme”

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J1432
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1444
The feasibility and biologic effect of a modified Atkins-based intermittent fasting diet in patients with high-grade astrocytoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1454
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J1480
My Pathway: MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS(Protocol Number: ML28897/PRO 02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1498
A Phase I Study of Intravaginally Administered Artesunate In Women with High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15106
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15117
J15117 - Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15119
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7–Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15145
Study of 18F-DCFPyL PET/CT in the Assessment of Patients with Renal Cell Carcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center

J15183
A Phase II Trial of Reirradiation Combined with Open Label Pembrolizumab in Patients with Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15195
J15195 - A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15203
Pilot Biomarker Study of Stereotactic Body Radiation Therapy for Prostate Cancer Oligometastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15214
A Pilot Study of Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15216
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men with Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15222
J15222: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15237
J15237: A Phase II Study of GM-CSF secreting allogeneic pancreatic cancer vaccine in combination with PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Locally Advanced Adenocarcinoma of the Pancreas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1553
A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients with History of HPV16 Associated Cervical Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1557
Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-ß receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1560
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk localized and Locally Advanced Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1564
“The IDEA Study (Individualized Decisions for Endocrine therapy Alone): A prospective, single-arm cohort study of patients receiving endocrine therapy alone (without radiotherapy) after breast conserving surgery for early-stage, post-menopausal breast cancer patients whose tumors have favorable biologic features”

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital, Sibley Memorial Hospital

J1568
J1568: A Randomized Study of a GM-CSF secreting allogeneic pancreatic cancer vaccine with or without a PD-1 Blockade Antibody (Nivolumab) and CD137 Agonist Antibody (Urelumab) for the Neoadjuvant and Adjuvant Treatment of Patients with Surgically Resectable Adenocarcinoma of the Pancreas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1607
A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-programmed Death-1 Monoclonal Antibody, in Patients with B-cell Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16107
Partnering Around Cancer Clinical Trials (PACCT)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16108
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16118
Randomized Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients in Complete or Near Complete Remission

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16121
Improving Outcomes for Younger Breast Cancer Survivors: A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors. The Pathways to Wellness (PTW) Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16131
A Phase 1b Study of Enzalutamide plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC) (Sponsor Protocol c15-160)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16138
Phase I Safety Study of Stereotactic Radiosurgery with Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects with Recurrent or Metastatic Chordoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16140
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimdine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CA209-649)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16146
IMAGE II: Individualized Molecular Analyses Guide Efforts in Breast Cancer – Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1615
A Phase 1/2 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors (Sponsor Protocol Number: D419NC00001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16156
Pembrolizumab in Patients with Leptomeningeal Disease

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore

J16158
Phase II randomized study of pembrolizumab with or without epigenetic modulation with CC-486 in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (TRIO026)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16161
A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16163
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16173
J16173-Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, with or without Cyclophosphamide and GVAX Pancreas Vaccine in Patients with Metastatic Pancreatic Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16175
A Phase I Study of Intra-anally Administered Artesunate in Patients with High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1618
A phase II study of definitive therapy for newly diagnosed men with oligometastatic prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1619
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1641
(CA018-001) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1649
A Nerve Sheath Tumor Bank from Patients with NF1

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1651
Phase 2 Study of Azacitidine in Combination with Pembrolizumab in Relapsed/ Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older ( equal to 65 Years) AML Patients

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1652
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155).

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1658
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Extensive Stage Small Cell Lung Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1672
A phase 2-3, multicenter, Randomized, Double-Blind Study of selinexor (KPT-330) versus placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1677
J1677- A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1682
Randomized Phase II Study of Neoadjuvant Nivolumab with and without Urelumab in Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1688
Regenerative Medicine to Restore Normal Hematopoiesis in Aplastic Anemia

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1689
A Phase 1 Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR1-4 Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors, followed by an Expansion Cohort in Patients with FGFR1, 2, 3, or 4 Genetic Alterations (Protocol No.: PRN1371-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1690
9875 Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1693
Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate and High-Risk Prostate Cancer – a Pilot and Biomarker Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1705
Study INCB 01158-101 (formerly known as CX-1158-101) Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1708
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17107
J17107 - A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Hormone Receptor-Positive Her2-Negative Breast Cancer (Morpheus-HR+ Breast Cancer)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17111
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma (C-145-04)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17117
A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (CO40016)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17118
Prospective evaluation of determinants of resistance to first-line therapy with an aromatase inhibitor (AI) and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor in hormone receptor (HR) positive metastatic breast cancer (MBC)

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J17120
Cancer, Obesity/Overweight and Insomnia (COIN) Study

Sites: Johns Hopkins Bayview Medical Center

J17121
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17122
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17127
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Protocol IT-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17128
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease [BMT CTN 1507]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17130
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17136
J17136: Feasibility and Efficacy of Neoadjuvant Cabozantinib plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients with Locally Advanced Hepatocellular Carcinoma (HCC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17138
Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function During Breast Cancer Chemotherapy: A Feasibility Study

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J17140
A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC) (GSK 204697).

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17143
J17143 - A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17149
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men with an Elevated PSA

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17158
Overcoming Checkpoint Inhibitor Resistance with Epigenetic Therapy in Urothelial Cancer (GU-114)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17159
J17159 - A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17168
A Phase 1b Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients with Resectable Solid Tumor Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17177
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors [CABL001A2301]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17181
A Pilot Study of Stereotactic Radiosurgical Hypophysectomy for Intractable Pain from Bone Metastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17183
Title: An Open-Label, Single-Arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients (3000-01-005)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17187
Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17189
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17191
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib) (CPDR001X2103)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17193
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects with Relapsed/ Refractory Multiple Myeloma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17194
A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17197
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer (Protocol 1205-201)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1737
Preservation of Cognition and Neuropsychiatric Functioning with Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1745
A pilot study to assess safety and feasibility of 5 fraction hypofractionated stereotactic radiosurgery (treating tumor and edema) along with standard temozolomide for newly diagnosed glioblastoma, including assessment of lymphocyte sparing effect.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital

J1756
J1756: A Phase II Clinical Trial of GVAX Pancreas Vaccine (with Cyclophosphamide) in Combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic Adenocarcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1764
J1764-A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1778
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors (sponsor protocol MS100015-0019)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1791
A Phase II, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma (CNIR178X2201)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1794
J1794 - A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1797
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy (sponsor protocol #SGN22E-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1798
J1798: A Phase 2 Clinical Trial of Entinostat in Combination with Nivolumab for Patients with Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1801
A Pilot Study to evaluate the pharmacokinetic, pharmacodynamic, and resistance profile to trametinib and dabrafenib in BRAF-V600E mutated recurrent gliomas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1804
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

J1807
J1807 - A Phase 1 Clinical Trial To Evaluate The Safety And Immunogenicity Of A Neoantigen DNA Vaccine Strategy In Pancreatic Cancer Patients Following Surgical Resection And Adjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1808
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors (ASTX029-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18102
J18102 - Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibition

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1811
A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18118
J18118 - The effect of CTLA4/PDL-1 Blockade following drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with intermediate stage of HCC using Durvalumab (MEDI4736) and Tremelimumab

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1812
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer [COMBAT-CRPC]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18125
A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1825
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors (CA224-048)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1826
Studying the Pathologic and Immunologic Response after Ablative Radiation in Stage I Non-Small Cell Lung Cancer (SPARC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1836
IMMUNe MOdulation in Early Stage Estrogen Receptor Positive Breast Cancer treated with NeoADjuvant Avelumab, Palbociclib, and Tamoxifen: the ImmunoADAPT study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1840
Radiation Immunodynamics: The Immune Response to Standard Therapy in Patients with Glioblastoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1847
J1847: A phase I/II study of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in combination in metastatic pancreatic cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1850
Biomarker Detection in Men with Relapsed Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1851
Randomized trial assessing induction of double strand breaks with androgen receptor partial agonist in patients on androgen suppression

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1865
"EARLY FEASIBILITY STUDY FOR EVALUATION OF THE TRACEIT® TISSUE SPACER FOR CREATING SPACE BETWEEN THE DUODENUM AND PANCREAS IN PATIENTS WITH BORDERLINE RESECTABLE OR LOCALLY ADVANCED PANCREATIC CANCER UNDERGOING A COURSE OF SBRT (THE TIPS PILOT STUDY)"

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1875
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) (15-1071)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1878
The Johns Hopkins Breast Cancer Program Initiative to Reduce the Discontinuation Rate of Adjuvant Endocrine Therapy through Symptom Monitoring and Management: A Feasibility Study

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J1883
A Phase 2 Non-randomized Open-label Study Examining the Effect of eFT508 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC) (eFT508-0009)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1885
Using 4R care sequences for lung cancer care: 4R is "Right Information and Right Care for the Right Patient at the Right time."

Sites: Johns Hopkins Bayview Medical Center

J1891
J1891 - A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1892
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations (HCRN GU15-262)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1897
Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer (HCRN GU16-287)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

N1301
Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

N1403
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA011104
A011104 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA011202
A011202 A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA011401
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA011502
A011502 A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer (The ABC Trial)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNA031501
A031501 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA0577
N0577 CODEL: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNA071601
A071601 Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA081105
A081105 Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

NCTNA151216
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

NCTNA221405
A221405 A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNB51
B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNB55
B55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (D081CC00006)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNE1910
E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNE4412
E4412 A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNE4512
E4512 A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Johns Hopkins Bayview Medical Center

NCTNEA1131
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy versus Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNEA4151
EA4151 A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEA5142
EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Sites: Johns Hopkins Bayview Medical Center, Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNEA8143
EA8143 A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEA8153
EA8153 Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNGY007
GY007 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNGY009
GY009 A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin / Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin / Bevacizumab in Platinum Resistant Ovarian Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNGY012
GY012 A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNGY016
GY016 A Phase II Study of MK-3475 (Pembrolizumab) and Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNMDS
NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Natural History Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNNBR003
BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNS1207
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu-Negative Breast Cancer

Sites: Sibley Memorial Hospital, Suburban Hospital

NCTNS1418
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than / equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNS1602
S1602 A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNS1609
S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAALL1231
AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAALL1621
AALL1621 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PANHL12P1
ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PAPEC1621I
APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

PARST1321
ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

SIB16134
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer

Sites: Sibley Memorial Hospital

TBCRC031
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (“AC”) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations – The INFORM BRCA 1/2 Study: Investigation of Neoadjuvant Chemotherapy for Mutation Carriers: BRCA1/2 (TBCRC 031)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

TBCRC034
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy (TBCRC 034)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

TBCRC039
Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (TBCRC039)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore